All In Biotech

Drug Trial Radar · NCT03139604

GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease

GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

Last checked: Nov 19, 2026Latest source record: Sep 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 439 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

439

Actual

Start

Jul 19, 2017

Primary completion

May 2, 2019

Study completion Jul 13, 2020

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
May 4, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate itacitinib or placebo in combination with corticosteroids as first-line treatment of participants with Grade II to IV acute graft-versus-host disease (aGVHD).

Conditions

  • Graft-versus-host Disease (GVHD)

Interventions

  • ItacitinibDrug

    Itacitinib at the protocol-defined dose administered orally once daily (QD) plus corticosteroids.

  • PlaceboDrug

    Matching placebo tablets administered orally once daily (QD) plus corticosteroids.

  • PrednisoneDrug

    Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.

  • MethylprednisoloneDrug

    Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose appropriate for the severity of disease as background treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate Based on Center for International Blood and Marrow Transplant Research (CIBMTR) Response IndexTime frame: Day 28

Locations

129 sites in 19 countries. Site status is shown where the registry gives one.

  • University of California, San Diego (UCSD) - Moores Cancer Center

    La Jolla, California

  • University of Southern California

    Los Angeles, California

  • University of California, Los Angeles (UCLA) - Medical Center

    Los Angeles, California

  • Stanford Cancer Center

    Stanford, California

  • University of Colorado - Aurora Cancer Center

    Aurora, Colorado

  • University of Florida (UF) - Division of Hematology & Oncology

    Gainesville, Florida

  • University of Miami - Sylvester Cancer Center

    Miami, Florida

  • Florida Hospital Cancer Institute

    Orlando, Florida

  • University of Illinois at Chicago

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • Advocate Lutheran General Hospital - Oncology Specialists SC

    Park Ridge, Illinois

  • Indiana University (IU) Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana

  • Indiana Blood and Marrow Transplant

    Indianapolis, Indiana

  • University of Iowa

    Iowa City, Iowa

  • University of Kansas Cancer Center

    Westwood, Kansas

  • Tulane University Medical Center

    New Orleans, Louisiana

  • University of Maryland Medical Center

    Baltimore, Maryland

  • Tufts Medical Center

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Henry Ford Hospital

    Detroit, Michigan

  • Spectrum Health

    Grand Rapids, Michigan

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • Washington University School of Medicine

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire

  • John Theurer Cancer Center At Hackensack UMC

    Hackensack, New Jersey

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Northwell Health

    Lake Success, New York

  • Columbia University

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Stony Brook University Medical Center

    Stony Brook, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Wake Forest Baptist Medical Center - Wake Forest University School of Medicine

    Winston-Salem, North Carolina

  • Oncology Hematology in Cincinnati

    Cincinnati, Ohio

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • The Ohio State University (OSU)

    Columbus, Ohio

  • University of Oklahoma - Health Sciences Center

    Oklahoma City, Oklahoma

Showing 40 of 129 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.